看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
7 ^) p4 C8 o* B* }+ T2 ~. c; D% }% Y& d* F* o
; l" i$ z( O+ u. h6 U UCurrently available feasibility data for possible combination strategies.
G& o! m, S# a( O( ^————————————————————————————————
( h# C8 s, t8 l; \Combination Feasibility according to preliminary data
B( E7 X$ c7 @# _——————————————————————————————————
0 i0 x. l- Q( M6 a$ }, ]& ]Bevacizumab + sorafenib Yes, reduced dose " h* B" a) x3 o6 j& v' B% Z
Bevacizumab + sunitinib† No ) N* c. R1 n, U3 }. g3 ~ w
Bevacizumab + temsirolimus Yes ' Q7 A/ v0 R2 S- w8 Y
Bevacizumab + everolimus Yes
4 v+ X3 X8 B2 W7 }4 q* ~# e4 vSorafenib + sunitinib ?
! X1 v$ H/ E# {" i+ U5 Q* ` ESorafenib + temsirolimus Yes, reduced dose
, ^ ?5 H/ K$ c& G. M+ ?* aSorafenib + everolimus Yes, reduced dose ) Q" V# c. \/ G: o- y5 k N) m
Sunitinib + temsirolimus† No
4 w5 x- M) I8 c1 {/ G4 B; YSunitinib + everolimus ?
2 v. m+ x0 ]+ x2 ^5 DTemsirolimus + everolimus ?
$ Q; W! B/ o' F1 J% u. U+ u. f————————————————————
. C: C# r7 r) S†Led to US FDA warning.
: V" n- W) c$ p# J0 w4 e?: As yet unattempted combination.( @, N+ F6 b* h! i5 ]2 x# }
|